Developer docs
API playgroundTry for free, no card

Search company profiles

CardioDx

Full company profile

uuid00032fy

Namestring
CardioDx
Websiteurl
cardiodx.com
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cardiovascular genomic diagnostics, in vitro diagnostics, AI-enabled diagnostics, clinical molecular testing, precision medicine diagnostics
Industry2 codes
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cardiovascular Genomic Diagnostics
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CardioDx is a cardiovascular genomic diagnostics company that develops and provides AI-enabled in vitro diagnostics (IVD) for clinical use. Its offerings apply proprietary artificial intelligence algorithms to clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing, delivering diagnostic information that clinicians use to enhance patient care, particularly in cardiovascular and precision-medicine applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CardioDx is a diagnostic company that develops AI-enabled in vitro diagnostics (IVD). The company competes on algorithm performance, data quality, and regulatory approval status in the AI-enabled IVD market. However, the provided sources do not contain specific product names, detailed descriptions, or portfolio information.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Myriad Genetics is a molecular diagnostics company focused on genomic tests that inform treatment decisions, particularly in oncology and other specialty areas. It is directly comparable to CardioDx as a specialty IVD franchise built on proprietary genomic assays sold into clinical practice, with a similar regulatory-and-reimbursement-driven business model.

TypeDirect peer
Description

Veracyte is a genomic diagnostics company that develops molecular tests leveraging RNA sequencing and AI to resolve diagnostic ambiguity in specialty areas. It is comparable to CardioDx in being a specialty IVD company combining genomic/AI analysis with regulatory-cleared LDT or IVD tests sold through clinical channels.

TypeDirect peer
Description

Guardant Health is a leading precision oncology company specializing in blood-based (liquid biopsy) genomic testing. It is comparable to CardioDx as a blood-sample-driven, AI-enabled specialty diagnostics franchise with regulatory clearances and a focus on non-invasive decision-support testing in a defined clinical specialty.

TypeBroad incumbent
Description

Exact Sciences is a major molecular diagnostics company, best known for Cologuard, with an expanding menu of genomic tests across multiple specialties following its acquisition of Genomic Health. It is comparable to CardioDx as a large-scale specialty IVD operator pursuing platform expansion via regulatory-cleared molecular tests and AI/ML-enabled analysis.

TypeDirect peer
Description

Genomic Health pioneered genomic diagnostics in oncology with the Oncotype DX test, a category-creating IVD franchise. It is directly comparable to CardioDx as a specialty genomic test developer whose commercial success hinged on clinical validation, regulatory milestones, and reimbursement — the same value drivers for a cardiovascular genomic IVD.

TypeBroad incumbent
Description

Foundation Medicine is a molecular information company providing genomic profiling services to oncologists, now owned by Roche. It is comparable to CardioDx as a high-complexity specialty genomic diagnostics franchise reliant on AI-assisted interpretation, clinical validation, and payer reimbursement — ultimately serving as a model for acquisition by large strategics.

TypeEmerging player
Description

NeoGenomics is a clinical diagnostics laboratory specializing in oncology genetic testing, with growing specialty franchise reach. It is comparable to CardioDx as a specialty clinical diagnostics franchise combining proprietary assays, AI/algorithm-driven interpretation, and a hospital/clinic go-to-market motion.

TypeDirect peer
Description

Natera is a cell-free DNA and genetic testing company whose core franchise spans reproductive health, oncology, and organ health. It is comparable to CardioDx as a specialty molecular diagnostics franchise with multiple cleared indications and a reimbursement- and clinical-evidence-driven commercial model.

TypeBroad incumbent
Description

Quest Diagnostics is one of the largest clinical laboratory services companies in the U.S., with an advanced diagnostics franchise including cardiovascular and genomic specialty tests. It is comparable to CardioDx as a scaled clinical lab buyer and partner-of-choice for specialty IVD developers seeking national distribution and payer coverage.

TypeBroad incumbent
Description

Labcorp is a leading global clinical laboratory network with significant specialty/esoteric diagnostics franchise and extensive payer reach. It is comparable to CardioDx both as a potential commercialization partner and as a competitive incumbent that operates in the cardiovascular diagnostics space with broad distribution and established reimbursement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CardioDx

Cardiovascular Genomic Diagnosticscardiodx.com

CardioDx firmographics

Firmographics
Name
CardioDx
Website
https://cardiodx.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

CardioDx industry classification

Industry
Product category
Cardiovascular Genomic Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)

Keywords

  • Cardiovascular genomic diagnostics
  • In vitro diagnostics
  • AI-enabled diagnostics
  • Clinical molecular testing
  • Precision medicine diagnostics

Where CardioDx is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Markets served

CardioDx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

CardioDx product offering

Product offering

Core offering

CardioDx is a cardiovascular genomic diagnostics company that develops and provides AI-enabled in vitro diagnostics (IVD) for clinical use. Its offerings apply proprietary artificial intelligence algorithms to clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing, delivering diagnostic information that clinicians use to enhance patient care, particularly in cardiovascular and precision-medicine applications.

Product overview

CardioDx is a diagnostic company that develops AI-enabled in vitro diagnostics (IVD). The company competes on algorithm performance, data quality, and regulatory approval status in the AI-enabled IVD market. However, the provided sources do not contain specific product names, detailed descriptions, or portfolio information.

Differentiator

Problem solved

Functional benefit

Companies that use CardioDx

Customer profile

Segments2 records

Ideal customer profiles2 records

CardioDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

CardioDx partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

CardioDx competitors and assessment

Company assessment

Direct peers

  • Myriad Genetics: Myriad Genetics is a molecular diagnostics company focused on genomic tests that inform treatment decisions, particularly in oncology and other specialty areas. It is directly comparable to CardioDx as a specialty IVD franchise built on proprietary genomic assays sold into clinical practice, with a similar regulatory-and-reimbursement-driven business model.
  • Veracyte: Veracyte is a genomic diagnostics company that develops molecular tests leveraging RNA sequencing and AI to resolve diagnostic ambiguity in specialty areas. It is comparable to CardioDx in being a specialty IVD company combining genomic/AI analysis with regulatory-cleared LDT or IVD tests sold through clinical channels.
  • Guardant Health: Guardant Health is a leading precision oncology company specializing in blood-based (liquid biopsy) genomic testing. It is comparable to CardioDx as a blood-sample-driven, AI-enabled specialty diagnostics franchise with regulatory clearances and a focus on non-invasive decision-support testing in a defined clinical specialty.
  • Genomic Health (acquired by Exact Sciences): Genomic Health pioneered genomic diagnostics in oncology with the Oncotype DX test, a category-creating IVD franchise. It is directly comparable to CardioDx as a specialty genomic test developer whose commercial success hinged on clinical validation, regulatory milestones, and reimbursement — the same value drivers for a cardiovascular genomic IVD.
  • Natera: Natera is a cell-free DNA and genetic testing company whose core franchise spans reproductive health, oncology, and organ health. It is comparable to CardioDx as a specialty molecular diagnostics franchise with multiple cleared indications and a reimbursement- and clinical-evidence-driven commercial model.

Broad incumbents

  • Exact Sciences: Exact Sciences is a major molecular diagnostics company, best known for Cologuard, with an expanding menu of genomic tests across multiple specialties following its acquisition of Genomic Health. It is comparable to CardioDx as a large-scale specialty IVD operator pursuing platform expansion via regulatory-cleared molecular tests and AI/ML-enabled analysis.
  • Foundation Medicine (Roche): Foundation Medicine is a molecular information company providing genomic profiling services to oncologists, now owned by Roche. It is comparable to CardioDx as a high-complexity specialty genomic diagnostics franchise reliant on AI-assisted interpretation, clinical validation, and payer reimbursement — ultimately serving as a model for acquisition by large strategics.
  • Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies in the U.S., with an advanced diagnostics franchise including cardiovascular and genomic specialty tests. It is comparable to CardioDx as a scaled clinical lab buyer and partner-of-choice for specialty IVD developers seeking national distribution and payer coverage.
  • Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network with significant specialty/esoteric diagnostics franchise and extensive payer reach. It is comparable to CardioDx both as a potential commercialization partner and as a competitive incumbent that operates in the cardiovascular diagnostics space with broad distribution and established reimbursement.

Emerging players

  • NeoGenomics: NeoGenomics is a clinical diagnostics laboratory specializing in oncology genetic testing, with growing specialty franchise reach. It is comparable to CardioDx as a specialty clinical diagnostics franchise combining proprietary assays, AI/algorithm-driven interpretation, and a hospital/clinic go-to-market motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

CardioDx social profiles

Digital presence

CardioDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CardioDx leadership team

Management profile

Number of profiles

Profiles1 record

CardioDx funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CardioDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioDx

What does CardioDx do?

CardioDx is a cardiovascular genomic diagnostics company that develops and provides AI-enabled in vitro diagnostics (IVD) for clinical use. Its offerings apply proprietary artificial intelligence algorithms to clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing, delivering diagnostic information that clinicians use to enhance patient care, particularly in cardiovascular and precision-medicine applications.

When was CardioDx founded?

CardioDx was founded in 2004. It employs 51 to 100 people.

Where is CardioDx based?

CardioDx is headquartered in Redwood City, United States, in the North America region.

Who are CardioDx's main competitors?

Direct peers on record are Myriad Genetics, Veracyte, Guardant Health, Genomic Health (acquired by Exact Sciences) and Natera. Broad incumbents are Exact Sciences, Foundation Medicine (Roche), Quest Diagnostics and Laboratory Corporation of America (Labcorp). NeoGenomics is listed as an emerging player.

Does CardioDx have an API?

No public API is recorded for CardioDx.

What industry is CardioDx in?

CardioDx's product category is Cardiovascular Genomic Diagnostics. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTimothy Henn, Experienced Genomics Diagnostics and Life Sciences Executive, Joins CardioDx as Chief Financial OfficerCardioDx appointed Timothy Henn as Chief Financial Officer, bringing over 15 years of healthcare executive experience. He previously served as CFO of Crescendo Biosciences, acquired by Myriad Genetics. The company plans to continue commercial expansion of its Corus CAD test.GlobeNewswireIt's Time to Spread the Word(TM) About Coronary Artery Disease and Women's HealthHealthyWomen, the National Association of Nurse Practitioners in Women's Health, and CardioDx launched the 'Spread the Word' campaign to educate women on coronary artery disease symptoms and testing options. Heart disease is the top killer of women, and the campaign aims to empower women to discuss testing with providers. A public service announcement debuts during February Heart Month.VC News DailyCardioDx Completes $58M Equity FinancingCardioDx, a cardiovascular genomic diagnostics company based in Palo Alto, California, announced completion of a $58 million two-tranche equity financing with participation from multiple investors including Temasek, Longitude Capital, Kleiner Perkins Caufield & Byers, J.P. Morgan, and others. Proceeds will support commercial expansion of the Corus CAD gene expression test and development of additional genomic diagnostics in cardiovascular disease. The financing follows a favorable Medicare coverage decision by Palmetto GBA establishing coverage for Corus CAD for over 40 million Medicare enrollees in the United States.FinSMEsCardioDx Closes $60m Financing RoundCardioDx closed a $60m equity financing round with new investors including Longitude Capital, J.P. Morgan, and existing backers. The company will use the funds to expand U.S. reimbursement coverage for its Corus CAD blood-based gene expression test and develop new cardiovascular genomic diagnostics products.FinSMEsCardioDx Raises $5M from GE Healthymagination FundCardioDx, a cardiovascular genomic diagnostics developer, raised $5M from the GE Healthymagination Fund, its first investment. The capital will advance and co-develop diagnostic technologies to improve care for patients with cardiovascular disease.